Could a new pill calm brain inflammation and slow Parkinson's-Linked sleep disorder?
NCT ID NCT05904717
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether an oral drug called PXS-4728A can reduce brain inflammation in 40 adults aged 50-80 with isolated REM sleep behavior disorder (iRBD), a condition often leading to Parkinson's disease. Participants receive either the drug or a placebo for 12 weeks, and brain scans measure inflammation changes. The goal is to see if the drug is safe and can slow disease progression.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ISOLATED RAPID EYE MOVEMENT SLEEP BEHAVIOR DISORDER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Clinical Neuroscience Nuffield Department of Clinical Neurosciences
Oxford, United Kingdom
-
Cognitive Neuroscience Brain & Mind Centre
Camperdown, Sydney, 2050, Australia
-
Parkinsons Disease Research Clinic - Macquarie University
Macquarie, New South Wales, 2109, Australia
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Skin, speech, and brain scans may unmask hidden neurodegeneration
- Heart scan may spot hidden brain disease
- Scientists track rare brain diseases to uncover early warning signs
- Could head injuries trigger a strange sleep disorder? new study investigates
- Gut check: could your intestines hold clues to Parkinson's and MS?
- Sleep disorder study could pave way for Parkinson's prevention